Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats

A recombinant adeno-associated virus (rAAV) vector capable of infecting cells and expressing rat glial cell line-derived neurotrophic factor (rGDNF), a putative central nervous system dopaminergic survival factor, under the control of a potent cytomegalovirus (CMV) immediate/early promoter (AAV-MD-rGDNF) was constructed. Two experiments were performed to evaluate the time course of expression of rAAV-mediated GDNF protein expression and to test the vector in an animal model of Parkinson’s disease. To evaluate the ability of rAAV-rGDNF to protect nigral dopaminergic neurons in the progressive Sauer and Oertel 6-hydroxydopamine (6-OHDA) lesion model, rats received perinigral injections of either rAAV-rGDNF virus or rAAV-lacZ control virus 3 weeks prior to a striatal 6-OHDA lesion and were sacrificed 4 weeks after 6-OHDA. Cell counts of back-labeled fluorogold-positive neurons in the substantia nigra revealed that rAAV-MD-rGDNF protected a significant number of cells when compared with cell counts of rAAV-CMV-lacZ-injected rats (94% vs. 51%, respectively). In close agreement, 85% of tyrosine hydroxylase-positive cells remained in the nigral rAAV-MD-rGDNF group vs. only 49% in the lacZ group. A separate group of rats were given identical perinigral virus injections and were sacrificed at 3 and 10 weeks after surgery. Nigral GDNF protein expression remained relatively stable over the 10 weeks investigated. These data indicate that the use of rAAV, a noncytopathic viral vector, can promote delivery of functional levels of GDNF in a degenerative model of Parkinson’s disease.

Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study

Objective: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls.

Depression as a risk factor for ischaemic heart disease in men: population based case-control study

Objective: To determine the relation between depression, anxiety, and use of antidepressants and the onset of ischaemic heart disease.

Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members

The development of Alzheimer's disease (AD) later in life may be reflective of environmental factors operating over the course of a lifetime. Educational and occupational attainments have been found to be protective against the development of the disease but participation in activities has received little attention. In a case-control study, we collected questionnaire data about 26 nonoccupational activities from ages 20 to 60. Participants included 193 people with probable or possible AD and 358 healthy control-group members. Activity patterns for intellectual, passive, and physical activities were classified by using an adaptation of a published scale in terms of “diversity” (total number of activities), “intensity” (hours per month), and “percentage intensity” (percentage of total activity hours devoted to each activity category). The control group was more active during midlife than the case group was for all three activity categories, even after controlling for age, gender, income adequacy, and education. The odds ratio for AD in those performing less than the mean value of activities was 3.85 (95% confidence interval: 2.65–5.58, P < 0.001). The increase in time devoted to intellectual activities from early adulthood (20–39) to middle adulthood (40–60) was associated with a significant decrease in the probability of membership in the case group. We conclude that diversity of activities and intensity of intellectual activities were reduced in patients with AD as compared with the control group. These findings may be because inactivity is a risk factor for the disease or because inactivity is a reflection of very early subclinical effects of the disease, or both.

Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.

Fabry disease is an X-linked metabolic disorder due to a deficiency of alpha-galactosidase A (alpha-gal A; EC 3.2.1.22). Patients accumulate glycosphingolipids with terminal alpha-galactosyl residues that come from intracellular synthesis, circulating metabolites, or from the biodegradation Of senescent cells. Patients eventually succumb to renal, cardio-, or cerebrovascular disease. No specific therapy exists. One possible approach to ameliorating this disorder is to target corrective gene transfer therapy to circulating hematopoietic cells. Toward this end, an amphotropic virus-producer cell line has been developed that produces a high titer (>10(6) i.p. per ml) recombinant retrovirus constructed to transduce and correct target cells. Virus-producer cells also demonstrate expression of large amounts of both intracellular and secreted alpha-gal A. To examine the utility of this therapeutic vector, skin fibroblasts from Fabry patients were corrected for the metabolic defect by infection with this recombinant virus and secreted enzyme was observed. Furthermore, the secreted enzyme was found to be taken up by uncorrected cells in a mannose-6-phosphate receptor-dependent manner. In related experiments, immortalized B cell lines from Fabry patients, created as a hematologic delivery test system, were transduced. As with the fibroblasts, transduced patient B cell lines demonstrated both endogenous enzyme correction and a small amount of secretion together with uptake by uncorrected cells. These studies demonstrate that endogenous metabolic correction in transduced cells, combined with secretion, may provide a continuous source of corrective material in trans to unmodified patient bystander cells (metabolic cooperativity).

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

The brain amyloid of Alzheimer disease (AD) may potentially be imaged in patients with AD by using neuroimaging technology and a radiolabeled form of the 40-residue beta-amyloid peptide A beta 1-40 that is enabled to undergo transport through the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo. Transport of 125I-labeled A beta 1-40 (125I-A beta 1-40) through the BBB was found to be negligible by experiments with both an intravenous injection technique and an internal carotid artery perfusion method in anesthetized rats. In addition, 125I-A beta 1-40 was rapidly metabolized after either intravenous injection or internal carotid artery perfusion. BBB transport was increased and peripheral metabolism was decreased by conjugation of monobiotinylated 125I-A beta 1-40 to a vector-mediated drug delivery system, which consisted of a conjugate of streptavidin (SA) and the OX26 monoclonal antibody to the rat transferrin receptor, which undergoes receptor-mediated transcytosis through the BBB. The brain uptake, expressed as percent of injected dose delivered per gram of brain, of the 125I,bio-A beta 1-40/SA-OX26 conjugate was 0.15 +/- 0.01, a level that is 2-fold greater than the brain uptake of morphine. The binding of the 125I,bio-A beta 1-40/SA-OX26 conjugate to the amyloid of AD brain was demonstrated by both film and emulsion autoradiography performed on frozen sections of AD brain. Binding of the 125I,bio-A beta 1-40/SA-OX26 conjugate to the amyloid of AD brain was completely inhibited by high concentrations of unlabeled A beta 1-40. In conclusion, these studies show that BBB transport and access to amyloid within brain may be achieved by conjugation of A beta 1-40 to a vector-mediated BBB drug delivery system.

Dispersión y genes relacionados con la resistencia a insecticidas en Triatoma infestans: su vinculación con el control del vector de la enfermedad de Chagas

Entre las especies transmisoras de la enfermedad de Chagas de mayor importancia a nivel sanitario se destaca Triatoma infestans, considerada el principal vector en América del Sur (entre las latitudes 10° y 46° S). Los programas de control de la transmisión de la enfermedad promueven la eliminación de las poblaciones del vector T. infestans mediante la fumigación con insecticidas en las regiones endémicas. Sin embargo, esta estrategia, presenta dificultades debido en parte a la extensión y variabilidad de las áreas endémicas y por otro lado, al tiempo requerido para prevenir la recuperación de las poblaciones tratadas con insecticidas. La efectividad a largo plazo de las campañas de control es en gran medida dependiente del conocimiento de la estructura de las poblaciones del vector. El análisis de la estructura genética con un enfoque filogeográfico de poblaciones del vector en regiones endémicas de Argentina, mediante secuencias de genes mitocondriales y nucleares descriptas por primera vez para ese fin, permitirá aportar nuevas bases para la comprensión de la dinámica y evolución de las poblaciones del insecto vector y resolver interrogantes sobre procesos como por ejemplo los de dispersión y recolonización de la especie transmisora que afectan en forma directa a la eficiencia de los intentos de control. Los patrones de dispersión de esta especie estarían estrechamente vinculados con la transmisión de la enfermedad de Chagas. Por lo tanto, esta información podría ser de utilidad para la optimización del diseño de las intervenciones de control a implementar en el área endémica que conducirían a una disminución del impacto que esta enfermedad provoca en la población. Por otra parte, se han observado fallas en el control del vector debido a la existencia de resistencia a los insecticidas piretroides. Entre los mecanismos que confieren resistencia a insecticidas se han descripto los que implican cambios en canales de sodio, conocido como resistencia “knockdown” (Kdr), y aquellos que provocan un aumento de la actividad de enzimas responsables de su metabolismo. Con respecto al último mecanismo, las evidencias sugieren que las enzimas mono-oxigenasas citocromo P450 tienen comunmente un rol primario en la resistencia a insecticidas piretroides. Incrementos en la expresión a nivel de la transcripción de genes de citocromos P450 (CYP450) son frecuentemente considerados responsables de aumentar el metabolismo de insecticidas y parece ser un fenómeno común en la evolución del desarrollo de resistencia en insectos. El estudio de la posible relación de genes CYP450, que proponemos caracterizar en T. infestans, con la resistencia a insecticidas podría aportar nuevas bases para el desarrollo del manejo de esa resistencia. Sin embargo, mientras que existen múltiples genes CYP450 en el genoma de insectos, sólo un gen NADPH citocromo P450 reductasa (CPR) existe en el genoma de cada insecto. Por este motivo, se propone también caracterizar en el vector este gen que codifica para una enzima que actúa en la transferencia de electrones desde la forma reducida de NADPH a los citocromos P450, así como investigar el efecto de su silenciamiento en poblaciones de T. infestans resistentes a insecticidas piretroides. Además, con el propósito de analizar si la existencia de resistencia a insecticidas piretroides puede ser el resultado de la acción de los citocromo P450 y/o de otros factores, se investigará en las poblaciones resistentes la posible existencia de una mutación de un gen de canal de sodio relacionada con resistencia a insecticidas (Kdr) que ha sido descripta para T. infestans. Este estudio proveería información de utilidad para el desarrollo de estrategias alternativas de control que serían de suma importancia en regiones en las que las poblaciones de este vector presentan resistencia a los insecticidas y, por lo tanto, tendría claramente implicancias importantes para el manejo de la resistencia en este vector.

First National Conference on Chronic Disease Prevention and Control : identifying effective strategies : September 9-11, 1986, Atlanta, Ga. : conference summary /

"March 1987."

Experimental studies on control of oak wilt disease /

Cover title.